Autolus Therapeutics plc American Depositary Share
$1.89
-$0.05 (-2.58%)
$1.88Day Range$1.96
Key Statistics
Market Cap
$503.05M
Shares Outstanding
266.2M
Primary Exchange
XNAS
Currency
USD
Type
ADRC
IPO Date
Jun 22, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$1.95
Day High
$1.96
Day Low
$1.88
Volume
978.7K
VWAP
$1.90
Prev Close
$1.94
Transactions
--
Acc. Volume
--
About Autolus Therapeutics plc American Depositary Share
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836752 employeesTHE MEDIAWORKS, LONDON, X0, W12 7FP44 20 3829 6230IPO Jun 22, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001730463
- Composite FIGI
- BBG00KVT05R6
- Share Class FIGI
- BBG00KVT06G6
- Ticker Root
- AUTL
- SIC Code
- 2836
About Autolus Therapeutics plc American Depositary Share (AUTL) Stock
Autolus Therapeutics plc American Depositary Share (AUTL) closed the 2026-09-15 session at $1.89, down 2.58% versus the previous close (-0.05). The stock opened at $1.95 and traded between $1.88 and $1.96 during that session. Session trading volume was 979K shares. The volume-weighted average price (VWAP) is $1.90.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
Autolus Therapeutics plc American Depositary Share has a market capitalization of $503.0 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. AUTL is listed on the XNAS exchange. The company employs approximately 752 people. Autolus Therapeutics plc American Depositary Share is headquartered in LONDON, X0. The recorded listing date is 2018-06-22.
On this page you can find market AUTL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.